Zevra Therapeutics, Inc. ZVRA Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive) at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.
The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zevra Therapeutics, Inc.'s total cash, cash equivalents, and restricted cash (inclusive).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zevra Therapeutics, Inc.'s total cash, cash equivalents, and restricted cash (inclusive)?
- Zevra Therapeutics, Inc. (ZVRA) reported total cash, cash equivalents, and restricted cash (inclusive) of $95.6M in Q1 2026.
- How has Zevra Therapeutics, Inc.'s total cash, cash equivalents, and restricted cash (inclusive) changed year-over-year?
- Zevra Therapeutics, Inc.'s total cash, cash equivalents, and restricted cash (inclusive) increased by 156.0% year-over-year, from $37.34M to $95.6M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s total cash, cash equivalents, and restricted cash (inclusive)?
- Over 2 years (2023 to 2025), Zevra Therapeutics, Inc.'s total cash, cash equivalents, and restricted cash (inclusive) has grown at a 20.4% compound annual growth rate (CAGR), from $43.05M to $62.41M.